FLT3 and acute myeloid leukemia: Upon confirmation of AML development at 4 weeks after transplantation, we treated these mice with the TKI AC220 [38] to target FLT3-ITD and cytoreduce AML blasts (20 mg/kg/day, oral gavage, Fig. 5a).